• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与 IgE 相关的特应性皮炎中的肠道微生物组和先天免疫反应模式。

Gut microbiome and innate immune response patterns in IgE-associated eczema.

机构信息

International Inflammation Network (in-FLAME) of the World Universities Network, Umeå, Sweden.

Department of Clinical Sciences, Pediatrics, Umeå University, Umeå, Sweden.

出版信息

Clin Exp Allergy. 2015 Sep;45(9):1419-29. doi: 10.1111/cea.12566.

DOI:10.1111/cea.12566
PMID:25944283
Abstract

BACKGROUND

Gut microbiome patterns have been associated with predisposition to eczema potentially through modulation of innate immune signalling.

OBJECTIVE

We examined gut microbiome development in the first year of life in relation to innate immune responses and onset of IgE-associated eczema over the first 2.5 years in predisposed children due to maternal atopy [www.anzctr.org.au, trial ID ACTRN12606000280505].

METHODS

Microbial composition and diversity were analysed with barcoded 16S rRNA 454 pyrosequencing in stool samples in pregnancy and at ages 1 week, 1 month and 12 months in infants (n = 10) who developed IgE-associated eczema and infants who remained free of any allergic symptoms at 2.5 years of age (n = 10). Microbiome data at 1 week and 1 month were analysed in relation to previously assessed immune responses to TLR 2 and 4 ligands at 6 months of age.

RESULTS

The relative abundance of Gram-positive Ruminococcaceae was lower at 1 week of age in infants developing IgE-associated eczema, compared with controls (P = 0.0047). At that age, the relative abundance of Ruminococcus was inversely associated with TLR2 induced IL-6 (-0.567, P = 0.042) and TNF-α (-0.597, P = 0.032); there was also an inverse association between the abundance of Proteobacteria (comprising Gram-negative taxa) and TLR4-induced TNF-α (rs = -0.629, P = 0.024). This relationship persisted at 1 month, with inverse associations between the relative abundance of Enterobacteriaceae (within the Proteobacteria phylum) and TLR4-induced TNF-α (rs = -0.697, P = 0.038) and Enterobacteriaceae and IL-6 (rs = -0.709, P = 0.035). Mothers whose infants developed IgE-associated eczema had lower α-diversity of Bacteroidetes (P = 0.04) although this was not seen later in their infants. At 1 year, α-diversity of Actinobacteria was lower in infants with IgE-associated eczema compared with controls (P = 0.002).

CONCLUSION AND CLINICAL RELEVANCE

Our findings suggest that reduced relative abundance of potentially immunomodulatory gut bacteria is associated with exaggerated inflammatory cytokine responses to TLR-ligands and subsequent development of IgE-associated eczema.

摘要

背景

肠道微生物组模式与特应性皮炎的易感性有关,可能通过调节先天免疫信号。

目的

我们研究了生命的第一年中肠道微生物组的发展与固有免疫反应的关系,并在有特应性母亲的儿童中,在 2.5 年内观察到 IgE 相关特应性皮炎的发病情况[www.anzctr.org.au,试验 ID ACTRN12606000280505]。

方法

在婴儿(n=10)怀孕和 1 周、1 个月和 12 个月时,用带条形码的 16S rRNA 454 焦磷酸测序分析粪便样本中的微生物组成和多样性,这些婴儿发展为 IgE 相关特应性皮炎,而在 2.5 岁时没有任何过敏症状的婴儿(n=10)。在 1 周和 1 个月时分析微生物组数据与 6 个月时对 TLR 2 和 4 配体的免疫反应。

结果

与对照组相比,发展为 IgE 相关特应性皮炎的婴儿在 1 周时肠道中革兰氏阳性 Ruminococcaceae 的相对丰度较低(P=0.0047)。在那个年龄,Ruminococcus 的相对丰度与 TLR2 诱导的 IL-6(-0.567,P=0.042)和 TNF-α(-0.597,P=0.032)呈负相关;变形菌门(包括革兰氏阴性分类群)的丰度与 TLR4 诱导的 TNF-α(rs=-0.629,P=0.024)之间也存在负相关。这种关系在 1 个月时仍然存在,肠杆菌科(变形菌门)与 TLR4 诱导的 TNF-α(rs=-0.697,P=0.038)和肠杆菌科与 IL-6(rs=-0.709,P=0.035)之间呈负相关。其婴儿发展为 IgE 相关特应性皮炎的母亲的拟杆菌门的 α-多样性较低(P=0.04),尽管在她们的婴儿中没有看到这种情况。在 1 岁时,与对照组相比,IgE 相关特应性皮炎患儿的放线菌门的 α-多样性较低(P=0.002)。

结论和临床相关性

我们的研究结果表明,潜在的免疫调节肠道细菌的相对丰度降低与 TLR-配体的过度炎症细胞因子反应和随后的 IgE 相关特应性皮炎的发展有关。

相似文献

1
Gut microbiome and innate immune response patterns in IgE-associated eczema.与 IgE 相关的特应性皮炎中的肠道微生物组和先天免疫反应模式。
Clin Exp Allergy. 2015 Sep;45(9):1419-29. doi: 10.1111/cea.12566.
2
Low diversity of the gut microbiota in infants with atopic eczema.特应性皮炎婴儿肠道微生物多样性较低。
J Allergy Clin Immunol. 2012 Feb;129(2):434-40, 440.e1-2. doi: 10.1016/j.jaci.2011.10.025. Epub 2011 Dec 6.
3
Temporal variations in early gut microbial colonization are associated with allergen-specific immunoglobulin E but not atopic eczema at 2 years of age.早期肠道微生物定植的时间变化与过敏原特异性免疫球蛋白 E 相关,但与 2 岁时的特应性皮炎无关。
Clin Exp Allergy. 2011 Nov;41(11):1545-54. doi: 10.1111/j.1365-2222.2011.03817.x. Epub 2011 Jul 13.
4
Low gut microbiota diversity in early infancy precedes asthma at school age.婴儿早期肠道微生物群多样性低是学龄期哮喘的先兆。
Clin Exp Allergy. 2014 Jun;44(6):842-50. doi: 10.1111/cea.12253.
5
Influence of early gut microbiota on the maturation of childhood mucosal and systemic immune responses.早期肠道微生物群对儿童黏膜和全身免疫应答成熟的影响。
Clin Exp Allergy. 2009 Dec;39(12):1842-51. doi: 10.1111/j.1365-2222.2009.03326.x. Epub 2009 Sep 3.
6
Molecular fingerprinting of the intestinal microbiota of infants in whom atopic eczema was or was not developing.对正在或未患特应性皮炎的婴儿肠道微生物群进行分子指纹分析。
Clin Exp Allergy. 2006 Dec;36(12):1602-8. doi: 10.1111/j.1365-2222.2006.02599.x.
7
Gut microbiota and development of atopic eczema in 3 European birth cohorts.3个欧洲出生队列中的肠道微生物群与特应性皮炎的发展
J Allergy Clin Immunol. 2007 Aug;120(2):343-50. doi: 10.1016/j.jaci.2007.05.018. Epub 2007 Jun 29.
8
Reduced gut microbial diversity in early life is associated with later development of eczema but not atopy in high-risk infants.生命早期肠道微生物多样性减少与高风险婴儿后期特应性皮炎的发生有关,但与特应性无关。
Pediatr Allergy Immunol. 2012 Nov;23(7):674-81. doi: 10.1111/j.1399-3038.2012.01328.x. Epub 2012 Jul 26.
9
Oral administration of Bifidobacterium bifidum TMC3115 to neonatal mice may alleviate IgE-mediated allergic risk in adulthood.口服双歧杆菌 TMC3115 可能会减轻新生期小鼠 IgE 介导的成年期过敏风险。
Benef Microbes. 2018 Sep 18;9(5):815-828. doi: 10.3920/BM2018.0005. Epub 2018 Jun 11.
10
Having older siblings is associated with gut microbiota development during early childhood.有哥哥姐姐与幼儿期肠道微生物群的发育有关。
BMC Microbiol. 2015 Aug 1;15:154. doi: 10.1186/s12866-015-0477-6.

引用本文的文献

1
The Role of Microbiota in the Pathogenesis of Bullous Pemphigoid and Pemphigus Vulgaris: Evidence, Controversies, and Perspectives.微生物群在大疱性类天疱疮和寻常型天疱疮发病机制中的作用:证据、争议与展望
Int J Mol Sci. 2025 Jun 24;26(13):6076. doi: 10.3390/ijms26136076.
2
NorthPop: a prospective population-based birth cohort study.北方人口研究:一项基于人群的前瞻性出生队列研究。
BMC Public Health. 2025 Jun 26;25(1):2171. doi: 10.1186/s12889-025-23561-y.
3
Probiotics in infants for prevention of allergic disease.婴儿使用益生菌预防过敏性疾病。
Cochrane Database Syst Rev. 2025 Jun 13;6(6):CD006475. doi: 10.1002/14651858.CD006475.pub3.
4
Skin and systemic infections in children with atopic dermatitis: review of the current evidence.特应性皮炎患儿的皮肤及全身感染:当前证据综述
Front Pediatr. 2025 May 14;13:1513969. doi: 10.3389/fped.2025.1513969. eCollection 2025.
5
Microbiome and pediatric leukemia, diabetes, and allergies: Systematic review and meta-analysis.微生物组与小儿白血病、糖尿病和过敏:系统评价与荟萃分析。
PLoS One. 2025 May 20;20(5):e0324167. doi: 10.1371/journal.pone.0324167. eCollection 2025.
6
Exploring Causal Relationships Between Gut Microbiota, Inflammatory Cytokines, and Inflammatory Dermatoses: A Mendelian Randomization Study.探索肠道微生物群、炎性细胞因子和炎症性皮肤病之间的因果关系:一项孟德尔随机化研究。
Clin Cosmet Investig Dermatol. 2025 Mar 13;18:579-592. doi: 10.2147/CCID.S496091. eCollection 2025.
7
Toll-like receptors in atopic dermatitis: pathogenesis and therapeutic implications.特应性皮炎中的Toll样受体:发病机制及治疗意义
Heliyon. 2025 Jan 31;11(3):e42226. doi: 10.1016/j.heliyon.2025.e42226. eCollection 2025 Feb 15.
8
Exploring the causal relationship between gut microbiota and atopic dermatitis: A Mendelian randomization study.探索肠道微生物群与特应性皮炎之间的因果关系:一项孟德尔随机化研究。
Medicine (Baltimore). 2024 Dec 27;103(52):e40193. doi: 10.1097/MD.0000000000040193.
9
Molecular mechanisms of obesity predisposes to atopic dermatitis.肥胖导致特应性皮炎的分子机制。
Front Immunol. 2024 Nov 4;15:1473105. doi: 10.3389/fimmu.2024.1473105. eCollection 2024.
10
The Association between Gut Microbiota and Serum Biomarkers in Children with Atopic Dermatitis.特应性皮炎患儿肠道微生物群与血清生物标志物之间的关联
Biomedicines. 2024 Oct 15;12(10):2351. doi: 10.3390/biomedicines12102351.